Cognyte Secures ~$5M Follow-On Order With National Intelligence Organization

Ongoing partnership and third order underscores confidence in Cognyte solutionsCognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced that it received an

Ongoing partnership and third order underscores confidence in Cognyte solutions

Cognyte Software Ltd. (NASDAQ:CGNT) (“Cognyte”), a global leader in investigative analytics software, today announced that it received an approximately $5 million additional order from a national intelligence organization in the Europe-Middle East-Africa (EMEA) region, for its solution that helps identify and prevent threats during operations.

Including this latest order, Cognyte has received three orders from this customer over the past year, serving as a testament to the superiority of the company’s technology. Through ongoing delivery of effective results, Cognyte’s solutions enhance operational efficiency and create substantial value for the customer’s operational teams.

“We have consistently delivered value to this customer with solutions that align to their evolving needs,” said Efi Nuri, Cognyte’s chief revenue officer. “The effectiveness of our technology, coupled with our ability to provide solutions that address the growing challenges our global customers face, continues to open opportunities for driving growth. We are pleased to expand our partnership with this customer and look forward to further collaboration.”

Total
0
Shares
Related Posts
Read More

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission rate(a) (based

JNJ